1. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 1993;91:2769–2775.

2. Antoni MH, August S, LaPerriere A, et al. Psychological and neuroendocrine measures related to functional immune changes in anticipation of HIV-1 serostatus notification. Psychosom Med 1990;52:496–510.

3. Atkinson JH, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan A. Prevalence of psychiatric disorders among men infected with the human immunodeficiency virus. Arch Gen Psychiatry 1988;48:859–864.

4. Baum S, Perkins DO, Gray-Silva S, Stern RA, Golden RN, Evans DL. Asymptomatic HIV infection and insomnia. Proceedings of the American Psychiatric Association. New Research Program and Abstracts, 1993.

5. Beach RS, Morgan R, Wilkie F, et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type-1-related cognitive changes. Arch Neurol 1992;49:501–506.

6. Berger JR, Laszovitz B, Post MJD, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. Ann Intern Med 1987;107:78–87.

7. Berger JR, Moskowitz L, Fischl M, Kelley RE. Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome. South Med J 1987;80:683–686.

8. Bornstein RA, Fama R, Rosenberger P, et al. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci 1993;5:254–259.

9. Bornstein RA, Podraza AM, Para MF, et al. Effect of minor head injury on neuropsychological performance in asymptomatic HIV-1 infection. Neuropsychology 1993;7:228–234.

10. Breitbart W. HIV-1 and delirium. Abstract presented at Psychopharmacology of HIV-1 infection: Clinical Challenges and Research Directions. NIMH, Office of AIDS Programs, Washington, DC, April 1993.

11. Brew BJ, Rosenblum M, Price RW. Pathogenetic implications of neuropathological findings in the AIDS dementia complex. Psychopharmacol Bull 1988;24:307–310.

12. Budka H. Neuropathology of human immunodeficiency virus. Brain Pathol 1991;1:163–175.

13. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993;270:2568–2573.

14. Chang SW, Katz MH, Hernadez S. The new AIDS case definition: implications for San Francisco. JAMA 1992;267:973–976.

15. Chrysikopoulos HS, Press GA, Grafe MR, Hesselink JR, Wiley CA. Encephalitis caused by human immunodeficiency virus: CT and MR imaging manifestations with clinical and pathologic correlation. Radiology 1990;175:185–191.

16. Day JJ, Grant I, Atkinson JH, et al. Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. J Neuropsychiatry Clin Neurosci 1992;4:15–20.

17. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364–367.

18. Evans DL, Edelsohn G, Golden R. Organic psychoses without anemia or spinal cord symptoms in vitamin B12 deficient patients. Am J Psychiatry 1983;140:218–221.

19. Evans DL, Folds JD, Petitto JM, et al. Circulating natural killer cell phenotypes in men and women with major depression. Arch Gen Psychiatry 1992;49:388–395.

20. Evans DL, Perkins DO. The clinical psychiatry of AIDS. Curr Opin Psychiatry 1990;3:96–102.

21. Evans DL, Smith MS, Golden RN. Antidepressants and HIV infection: effect of lithium chloride and desipramine and HIV replication. Depression 1993;1:205–209.

22. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrency and survival 6 years later. Arch Gen Psychiatry 1993;50:681–689.

23. Fawzy FI, Kemeny ME, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990;47:729–735.

24. Fernandez F, Levy JK. Psychopharmacoptherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection. Psychiatr Med 1991;9:377–396.

25. Fernandez F, Levy JK, Ruiz P. The use of methylphenidate in HIV patients: a clinical perspective. In: Grant I, Martin A, eds. Neuropsychology of HIV infection. New York: Oxford University Press, 1994;295–309.

26. Gibbs A, Andrews DG, Szmukler G, Mulhall B, Bowden SC. Early HIV-related neuropsychological impairment: relationship to stage of viral infection. J Clin Exp Neuropsychol 1990;12:766–780.

27. Gorman JM, Mayeux R, Stern Y, et al. The effect of zidovudine on neuropsychiatric measures in HIV-infected men. Am J Psychiatry 1993;150:505–507.

28. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Ann Intern Med 1987;107:828–836.

29. Grant I, Martin A, eds. Neuropsychology of HIV infection. New York: Oxford University Press, 1994.

30. Grant I, Olshen RA, Atkinson JH, et al. Depressed mood does not explain neuropsychological deficits in HIV-infected persons. Neuropsychology 1993;7:53–61.

31. Helsing KJ, Szklo M, Comstock GW. Factors associated with mortality after widowhood. Am J Public Health 1981;71:802–809.

32. Hinkin CH, van Gorp WG, Satz P, Weisman JD, Thommes J, Buckingham S. Depressed mood and its relationship to neuropsychological test performance in HIV-1 seropositive individuals. J Clin Exp Neuropsychol 1992;14:289–297.

33. Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989;50:5–8.

34. Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am Journal Psychiatry 1991;148:1558–1561.

35. Ironson G, LaPerriere A, Antoni M, et al. Changes in immune and psychological measures as a function of anticipation and reaction to news of HIV-1 antibody status. Psychosom Med 1990;52:247–270.

36. Jacobsen PB, Perry SW, Hirsch DA. Behavioral and psychological effects of HIV antibody testing. J Consult Clin Psychol 1990;58:31–37.

37. Janssen RS. Epidemiology of human immunodeficiency virus infection and the neurological complications of the infection. Semin Neurol 1992;12:10–17.

38. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a working group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778–785.

39. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992;42:1472–1476.

40. Jarvik JG, Lenkinski RE, Grossman RI, Gomori JM, Schnall MD, Frank I. Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 1993;186:739–744.

41. Jernigan TL, Archibald S, Hesselink JR, et al. Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. Arch Neurol 1993;50:250–255.

42. Keiburtz KD, Ketonen L, Zettelmaier AE, Kido D, Caine ED, Simon JH. Magnetic resonance imaging findings in HIV-1 cognitive impairment. Arch Neurol 1990;47:643–645.

43. Kertzner RM, Goetz R, Todak G, et al. Cortisol levels, immune status, and mood in homosexual men with and without HIV infection. Am J Psychiatry 1993;150:1674–1678.

44. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233:1089–1093.

45. Kovner R, Perecman E, Lazar W, et al. Relation of personality and attentional factors to cognitive deficits in human immunodeficiency virus: infected subjects. Arch Neurol 1989;46:274–277.

46. Leserman J, Perkins DO, Evans DL. Coping with the threat of AIDS: the role of social support. Am J Psychiatry 1992;149:1514–1520.

47. Levine S, Anderson D, Bystritsky A. A report of eight HIVseropositive patients with major depression responding to fluoxetine. J AIDS 1990;3:1074–1077.

48. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211–222.

49. Lyketsos CG, Hanson AL, Fishman M, Rosenblatt A, McHugh PR, Treisman GJ. Manic syndrome early and late in the course of HIV. Am J Psychiatry 1993;150:326–327.

50. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA 1993;270:2563–2567.

51. Marder K, Stern Y, Malouf R, et al. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome: relationship to head injury. Arch Neurol 1992;49:1169–1175.

52. Markowitz JC, Klerman GL, Perry SW. Interpersonal psychotherapy of depressed HIV-seropositive patients. Hosp Community Psychiatry 1992;43:885–890.

53. Martin A, Heyes MP, Salazar AM, Law WA, Williams J. Impaired motor-skill learning, slowed reaction time, and elevated cerebrospinal-fluid quinolinic acid in a subgroup of HIV-infected individuals. Neuropsychology 1993;7:149–157.

54. Masdeu JC, Yudd A, VanHeertum RL. Single photon emission computerized tomography in small multifocal perfusion defects in human immunodeficiency virus encephalopathy: a preliminary report. J Nucl Med 1991;32:1471–1475.

55. Mayeux R, Stern Y, Tang M-X, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993;43:176–182.

56. McKegney FP, O'Dowd MA. Suicidality and HIV status. Am J Psychiatry 1992;149:396–398.

57. Miller AH, Asnis GM, van Praag HM, Norin AJ. Influence of desmethylimipramine on natural killer cell activity. Psychiatry Res 1986;19:9–15.

58. Moeller AA, Oechsner M, Backmund HC, Popescu M, Emminger C, Holsboer F. Self-reported sleep quality in HIV infection: correlation to the stage of infection and zidovudine therapy. J AIDS 1991;4:1000–1003.

59. Moulton JM, Stempel RR, Bacchetti P, Temoshok L, Moss AR. Results of a one year longitudinal study of HIV antibody test notification from the San Francisco General Hospital Cohort, J AIDS 1991;4:787–794.

60. Namir S, Wolcott DL, Fawzy FI, Alumbaugh MJ. Coping with AIDS: psychological and health implications. J Appl Soc Psychol 1987;17:309–328.

61. Navia BA, Jordon BD, Price RW. The AIDS dementia complex, 1: clinical features. Ann Neurol 1986;19:517–524.

62. Navia BA, Price RW. The acquired immunodeficiency syndrome dementa complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 1987;44:65–69.

63. Norman SE, Chediak AD, Freeman C, Kiel M, Mendez A, Duncan R, Simoneau J, Nolan B. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep 1992; 15:150–155.

64. Pakesch G, Loimer N, Grunberger J, Pfersmann D, Linzmayer L, Mayerhofer S. Neuropsychological findings and psychiatric symptoms in HIV-1 infected and noninfected drug users. Psychiatry Res 1992;41:163–177.

65. Patterson TL, Semple S, Temoshok L, Atkinson JH, McCutchan JA, Grant I. Stress and depression predict immune change among HIV-infected men. Abstract presented at the 101st Annual Meeting of the American Psychological Association, Toronto, Canada, August 1993.

66. Perkins DO, Davidson EJ, Leserman J, Liao D, Evans DL. Personality disorder in men infected with HIV: a controlled study with implications for clinical care. Am J Psychiatry 1993;150:309–315.

67. Perkins DO, Evans DL. Fluoxetine treatment of depression in patients with HIV infection. Am J Psychiatry 1991;148:807–808.

68. Perkins DO, Leserman J, Gilmore JH, Petitto JM, Evans DL. Stress, depression, and immunity: research findings and clinical implications. In: N. Plotnikoff, A. Murgo, R. Faith, and J. Wybran, eds. Stress and immunity. London: CRC Press, 1991;167–188.

69. Perkins DO, Leserman J, Gray-Silva S, Baum SF, Stern RA, Evans DL. Fatigue and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Proceedings of the American Psychiatric Association. New Research Program and Abstracts, 1993.

70. Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Mood disorders in HIV infection: prevalence and risk factors in a non-epicenter of the AIDS epidemic. Am J Psychiatry 1994;151:233–236.

71. Perry S, Fishman B, Jacobsberg L, Frances A. Relationship over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry 1992;49:396–401.

72. Perry S, Fishman B, Jacobsberg LB, Young J, Frances A. Effectiveness of psychoeducational interventions in reducing emotional distress after HIV antibody testing. Arch Gen Psychiatry 1991;48:143–147.

73. Perry S, Jacobsberg L, Fishman B. Suicidal ideation and HIV testing. JAMA 1990;263:679–682.

74. Perry S, Jacobsberg LB, Fishman B, Frances A, Bob J, Jacobsberg BK. Psychiatric diagnosis before serological testing for the human immunodeficiency virus. Am J Psychiatry 1990;147:89–93.

75. Perry SW, Jacobsberg LB, Fishman B, Weiler PH, Gold JWM, Frances AJ. Psychological responses to serological testing for HIV. AIDS 1990;4:145–152.

76. Post MJD, Berger JR, Quencer RM. Asymptomatic and neurologically symptomatic HIV-1-seropositive individuals: prospective evaluation with cranial MR imaging. Radiology 1991;178:131–139.

77. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079–1083.

78. Price RW, Sidtis J, Rosenblum M. The AIDS dementia complex: some current questions. Ann Neurol 1988;23:S27–S33.

79. Rabkin JG. Psychostimulant medication for depression and lethargy in HIV illness: a pilot study. Newsletter Am Soc Clin Psychopharmacol 1994;[in press].

80. Rabkin JG, Harrison WM. Effect of imipramine on depression and immune status in a sample of men with HIV infection. Am J Psychiatry 1990;147:495–497.

81. Rabkin JG, Williams JBW, Reimien RH, Goetz R, Kertzner R, Gorman J. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIVpositive homosexual men. Arch Gen Psychiatry 1991;48:111–119.

82. Reiger DA, Boyd JH, Rae DS, et al. One month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988;45:977–986.

83. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double blind, placebo-controlled trial. N Engl J Med 1987;317:192–197.

84. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949–958.

85. Robertson KR, Stern RA, Hall CD, et al. The relationship of vitamin B12 deficiency to nervous system disease in human immunodeficiency virus seropositive individuals. Arch Neurol 1993; 50:807–811.

86. Rundell JR, Kyle KM, Brown GR, Thomason JL. Risk factors for suicide attempts in a human immunodeficiency virus screening program. Psychosomatics 1992;33:24–27.

87. Satz P, Morgenstern H, Miller EN, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study. J AIDS 1993;6:503–511.

88. Schielke E, Tatsch K, Pfister HW, et al. Reduced cerebral blood flow in early stages of human immunodeficiency virus infection. Arch Neurol 1990;47:1342–1345.

89. Schliefer SJ, Keller SE, Meyerson AT, et al. Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 1985;42:129–133.

90. Schmitt FA, Dickson LR, Brouwers P. Neuropsychological response to antiretroviral therapy in HIV infection. In: Grant I, Martin A, eds. Neuropsychology of HIV infection. New York: Oxford University Press, 1994;276–294.

91. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;2:888–891.

92. Stein M, Miller AH, Trestman RL. Depression, the immune system, and health and illness. Arch Gen Psychiatry 1991;48:171–177.

93. Stern RA, Singer NG, Silva SG, et al. Neurobehavioral functioning in a nonconfounded group of asymptomatic HIV-seropositive homosexual men. Am J Psychiatry 1992;149:1099–1102.

94. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7:683–692.

95. Tran Dinh YR, Mamo H, Cervoni J, Caulin C, Saimot AC. Disturbances in the cerebral perfusion of human immune deficiency virus-1 seropositive asymptomatic subjects: a quantitative tomography study of 18 cases. J Nucl Med 1990;31:1601–1607.

96. vanGorp WG, Mandelkern MA, Gee M, et al. Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia. J Neuropsychiatry Clin Neurosci 1992;4:280–287.

97. Wilkie FL, Morgan R, Fletcher MA, et al. Cognition and immune function in HIV-1 infection. AIDS 1992;6:977–981.

98. Wilkins JW, Robertson KR, van der Horst C, Robertson WT, Fryer JG, Hall CD. The importance of confounding factors in the evaluation of neuropsychological changes in patients infected with human immunodeficiency virus. J AIDS 1990;3:938–942.

99. Williams JBW, Rabkin JG, Remien RH, Gorman JM, Ehrhardt AA. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection: standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry 1991;48:124–130.

100. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/activity profile of 2¢,3¢-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526–529.